Aficamten – Medxy AI

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

By MedXY 09/10/2025

A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).

Clinical Updates Wellness & Lifestyle

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY 09/05/2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the SEQUOIA-HCM trial.

Clinical Updates Wellness & Lifestyle

Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity

By MedXY 08/17/2025

Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.

Clinical Updates Wellness & Lifestyle

Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy

By MedXY 08/17/2025

Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.